USP9X mediates an acute adaptive response to MAPK suppression in pancreatic cancer but creates multiple actionable therapeutic vulnerabilities

Pancreatic ductal adenocarcinomas (PDACs) frequently harbor KRAS mutations. Although MEK inhibitors represent a plausible therapeutic option, most PDACs are innately resistant to these agents. Here, we identify a critical adaptive response that mediates resistance. Specifically, we show that MEK inh...

Descripción completa

Detalles Bibliográficos
Autores principales: Perurena, Naiara, Lock, Rebecca, Davis, Rachel A., Raghavan, Srivatsan, Pilla, Natalie F., Ng, Raymond, Loi, Patrick, Guild, Caroline J., Miller, Abigail L., Sicinska, Ewa, Cleary, James M., Rubinson, Douglas A., Wolpin, Brian M., Gray, Nathanael S., Santagata, Sandro, Hahn, William C., Morton, Jennifer P., Sansom, Owen J., Aguirre, Andrew J., Cichowski, Karen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10140597/
https://www.ncbi.nlm.nih.gov/pubmed/37030295
http://dx.doi.org/10.1016/j.xcrm.2023.101007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10140597/
https://www.ncbi.nlm.nih.gov/pubmed/37030295
http://dx.doi.org/10.1016/j.xcrm.2023.101007

Ejemplares similares